Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Adult Patients With Metastatic Ocular Melanoma
NCT00421317Phase 2Terminated
- Sponsor
- Centre Oscar Lambret
- Start
- Dec 2005
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Ocular melanoma (OM), sponsored by Centre Oscar Lambret. Primary endpoint: Progression-free rate at 3 months. Started Dec 2005; status: terminated.
02
Drugs
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT00421317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421317.